· Dresden 2006 - Vom Nihilismus zum Algorithmus ·

Immunsuppressive Behandlungsstragien bei myelodysplastischen Syndromen mit niedrigem Risiko

Literatur | Vortrag siehe hier

Autor: Prof. Dr. med. Arnold Ganser, Medizinische Hochschule Hannover, Hannover

Quellenangabe: Deutsches MDS-Forum - Dresden 2006

Stand: 27.11.2006

Aivado M, Rong A, Stadler M.
Favourable resopnse to antithymocyte or antilymphocyte globulin in low-risk myelodysplastic syndrome patients with a "non-clonal" pattern of X-chromosome inactivation in bone marrow cells.
Eur J Haematol 2002;68:210-216. PM:12071936
[Medline]
Bouscary D, De Vos J, Guesnu M.
Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes.
Leukemia 1997;11:839-845. PM:9177438
[Medline]
Broliden PA, Dahl IM, Hast R.
Antthymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes.
Haematologica 2006;91:667-670. PM:16670072
[Medline]
Francis GE, Wing MA, Miller EJ, Berney JJ, Wonke B, Hoffbrand AV.
Use of bone marrow culture in prediction of acute leukaemic transformation in pre-leukaemia.
Lancet 1983;1:1409-1412. PM:6134182
[Medline]
Gersuk GM, Beckham C, Loken MR.
A role for tumour necrosis factor-alpha, Fas and Fas-ligand in marrow failure associated with myelodysplastic syndrome.
Br J Haematol 1998;103:176-188. PM:9792306
[Medline]
Huh YO, Jilani I, Estey E.
More cell death in refractory anemia with excess blasts in transformation than in acute myeloid leukemia.
Leukemia 2002;16:2249-2252. PM:12399969
[Medline]
Janasova A, Neuwirtova R, Cermak J, Vozobulova V, Mocikova K, Siskova M, Hochova I.
Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow.
Br J Haematol 1998;100:304-309. PM:9488617
[Medline]
Karadimitris A, Li K, Notaro R.
Association of clonal T-cell large granular lymphocyte disease and paroxysmal nocturnal haemoglobinuria (PNH): further evidence for a pathognetic link between T cells, aplastic anaemia and PNH.
Br J Haematol 2001;114:1010-1014. PM:11843843
[Medline]
Killick SB; Mufti G, Cavenagh JD.
A pilot study of antithymocyte globulin (ATG) in the treatment of patients with low-risk’ myelodysplasia.
Br J Haematol 2003;120:679-684. PM:12588356
[Medline]
Kochenderfer JN, Kobayashi S,Wieder ED, Su C, Molldrem JJ.
Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression.
Blood 2002;100:639-645. PM:12393644
[Medline]
Kurotaki H, Tsushima Y, Nagai K, Yagihashi S.
Apoptosis, bcl-2 expression and p53 accumulation in myelodysplastic syndrome, myelodysplastic-syndrome-derived acute myelogenous leukemia and de novo acute myelogenous leukemia.
Acta Haematol 2000;102:115-123. PM:10692673
[Medline]
Maciejewski JP, Risitano AM, Sloand EM.
A pilot study of the recombinant soluble human tumour necrosis factor receptor (p75)-Fc fusion protein in patients with myelodysplastic syndrome.
Br J Haematol 2002;117:119-126. PM:11918541
[Medline]
Molldrem JJ, Caples M, Mavroudis D, Plante M,Young NS, Barrett AJ.
Antithymocyte globulin for patients with myelodysplastic syndrome.
Br J Haematol 1997;99:699-705. PM:9401087
[Medline]
Molldrem JJ, Jiang YZ, Stetler-Stevenson M, Mavroudis D, Hensel N, Barrett AJ.
Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocytemediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles.
Br J Haematol 1998;102:1314-1322. PM:9753062
[Medline]
Molldrem JJ, Leifer E, Bahceci E.
Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes.
Ann Intern Med 2002;137:156-163. PM:12160363
[Medline]
Parker JE, Mufti GJ.
Excessive apoptosis in low risk myelodysplastic syndromes (MDS).
Leuk Lymphoma 2000;40:1-24. PM:11426609
[Medline]
Rajapaksa R, Ginzton N, Rott LS, Greenberg PL.
Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells.
Blood 1996;88:4275-4284. PM:8943864
[Medline]
Raza A, Gezer S, Mundle S.
Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes.
Blood 1995;86:268-276. PM:7795232
[Medline]
Sashida G, Ohyashiki JH, Nakajima A.
Telomere dynamics in myelodysplastic syndrome determined by telomere measurement of marrow metaphases.
Clin Cancer Res 2003;9:1489-1496. PM:12684424
[Medline]
Saunthararajah Y, Nakamura R, Nam JM.
HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndromes.
Blood 2002;100:1570-1574. PM:12176872
[Medline]
Saunthararajah Y, Nakamura R, Wesley R,Barrett AJ.
A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndromes.
Blood 102:3025-3027. PM:12829603
[Medline]
Stadler M, Germing U, Kliche KO.
A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes.
Leukemia 18:460-465. PM:14712285
[Medline]
Stasi R, Amadori S.
Infliximab chimaeric anti-tumour necrosis factor alpha monoclonal antibody treatment for patients with myelodysplastic syndromes.
Br J Haematol 2002;116:334-337. PM:11841434
[Medline]
Steensma DP, Dispenzieri A, Moore SB, Schroeder G, Tefferi A.
Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome.
Blood 2003;101:2156-2158. PM:12411290
[Medline]
Stifter G, Heiss S, Gastl G, Tzankov A, Stauder R.
Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis.
Eur J Haematol 2005;75:485-491. PM:16313260
[Medline]
Verhoef GE, De Schouwer P, Ceuppens JL, Van Damme J, Goossens W, Boogaerts MA.
Measurement of serum cytokine levels in patients with myelodysplastic syndromes.
Leukemia 1992;6:1268-1272. PM:1280751
[Medline]
Yazji S, Giles FJ, Tsimberidou AM.
Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes.
Leukemia 2003;17:2101-2106. PM:12931212
[Medline]